Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALinC 17 Classification and Induction for ALL
NCT01225874Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Dec 1999
- Primary completion
- Mar 2006
- Modality
- Monoclonal Antibodies, Therapeutic Enzymes, Lipid-based Nanoparticles
01
Overview
A Phase 3 trial of pegaspargase, vincristine sulfate liposome injection, dexamethasone, prednisone, daunorubicin in acute lymphoblastic leukemia (ALL), sponsored by Children's Oncology Group. Started Dec 1999; status: completed.
02
Drugs
pegaspargasevincristine sulfate liposome injectiondexamethasoneprednisonedaunorubicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01225874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01225874.